Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced that CEO Markus Warmuth, M.D. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will focus on the company's development of novel molecular glue degrader-based medicines.
  • None.
  • None.

BOSTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PT.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at, and an archived version will be made available for 30 days following the presentation.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit

Andrew Funderburk, Kendall IR

Cory Tromblee, Scient PR

Markus Warmuth, M.D. is scheduled to present at the conference on January 10, 2024 at 3:00 p.m. PT.

The webcast will be accessible via the 'Events & Presentations' section of Monte Rosa's website at

An archived version of the presentation will be available for 30 days following the event.
Monte Rosa Therapeutics Inc


GLUE Rankings

GLUE Latest News

GLUE Stock Data

Biological Product (except Diagnostic) Manufacturing

About GLUE

small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.